Galecto Inc (GLTO) - Total Liabilities
Based on the latest financial reports, Galecto Inc (GLTO) has total liabilities worth $25.18 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Galecto Inc to track the company's year-over-year net asset growth rate.
Galecto Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Galecto Inc's total liabilities have evolved over time, based on quarterly financial data. See Galecto Inc (GLTO) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Galecto Inc Competitors by Total Liabilities
The table below lists competitors of Galecto Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Bright Power Semiconductor
SHG:688368
|
China | CN¥802.06 Million |
|
Inox Wind Limited
NSE:INOXWIND
|
India | Rs27.50 Billion |
|
La-Z-Boy Incorporated
NYSE:LZB
|
USA | $1.03 Billion |
|
Anhui Andeli Department Store Co Ltd
SHG:603031
|
China | CN¥2.74 Billion |
|
American Bitcoin Corp
NASDAQ:ABTC
|
USA | $609.17 Million |
|
Changchun UP Optotech Co Ltd
SHE:002338
|
China | CN¥872.68 Million |
|
Chongqing Iron & Steel Co Ltd Class A
SHG:601005
|
China | CN¥18.67 Billion |
|
Deutsche EuroShop AG
F:DEQ
|
Germany | €2.70 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Galecto Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Galecto Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galecto Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galecto Inc (2018–2025)
The table below shows the annual total liabilities of Galecto Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.15 Million | +1448.58% |
| 2024-12-31 | $1.30 Million | -77.93% |
| 2023-12-31 | $5.90 Million | -48.44% |
| 2022-12-31 | $11.44 Million | +129.07% |
| 2021-12-31 | $4.99 Million | -18.26% |
| 2020-12-31 | $6.11 Million | -24.96% |
| 2019-12-31 | $8.14 Million | +83.12% |
| 2018-12-31 | $4.44 Million | -- |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more